Get the Stockscreener App
10.36
5.65%
-0.62
Pre-market:
10.35
-0.010
-0.10%
Promis Neurosciences Inc stock is traded at $10.36, with a volume of 33,830.
It is down -5.65% in the last 24 hours and down -7.83% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$10.98
Open:
$10.98
24h Volume:
33,830
Relative Volume:
0.79
Market Cap:
$92.91M
Revenue:
-
Net Income/Loss:
$-39.72M
P/E Ratio:
-0.5644
EPS:
-18.3554
Net Cash Flow:
$-28.18M
1W Performance:
-2.72%
1M Performance:
-7.83%
6M Performance:
+43.14%
1Y Performance:
-17.94%
1-Day Range:
$10.36
$10.98
1-Week Range:
$10.36
$11.00
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
10.36 | 98.47M | 0 | -39.72M | -28.18M | -18.36 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Stock (PMN) Latest News
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
ProMIS Neurosciences Inc. Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
TradingKey - TradingKey
ProMIS Neurosciences Releases Q1 2026 Financial Results - AlphaStreet
ProMIS Neurosciences Reports Q1 2026 Results, Advances Alzheimer’s PMN310 Trial and Secures $175M Financing - Minichart
ProMIS Neurosciences (PMN) Q1 2026 Earnings: EPS N/A, Revenue N/ - GuruFocus
ProMIS (PMN) Targets Alzheimer's Treatment with Promising Trial and Funding - GuruFocus
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences Inc. Q1 2026: Net income $(8.24M), Diluted EPS $(1.26) — 10-Q Summary - TradingView
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ProMIS Neurosciences Inc. Quarterly Earnings Report - Stock Titan
ProMIS Neurosciences (Nasdaq: PMN) boosts cash with $175M financing and advances PMN310 - Stock Titan
ProMIS Neurosciences Inc. Closes PIPE Financing of Up to $175 Million to Support Alzheimer's Disease Clinical Trial - Quiver Quantitative
Alzheimer's trial fully enrolled as ProMIS funds work through 2027 - Stock Titan
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights - ChartMill
ProMIS Neurosciences (PMN) owners report 181,632 shares (2.0%) in 13G/A amendment - Stock Titan
Insider Purchase: Director at $PMN Buys 4,000 Shares - Moomoo
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
PMN Price Today: ProMIS Neurosciences Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Director Kirwin’s entity buys 4,000 ProMIS (PMN) shares at $11.33 - Stock Titan
PMN ProMIS Neurosciences Inc. Common Shares (ON) posts wider than expected Q4 2025 loss but still notches small share price gain today.Equity Raise - UBND thành phố Hải Phòng
ProMIS (PMN) Stock: Is It Overpriced in Market (Drifts Lower) 2026-04-18Fast Rising Stocks - Cổng thông tin điện tử tỉnh Lào Cai
CEO Neil Warma to outline Alzheimer’s trial timeline at Apr. 21 event - Stock Titan
Winners Losers: Is ProMIS Neurosciences Inc stock a hidden gem2026 Breakouts & Breakdowns & Weekly High Return Forecasts - baoquankhu1.vn
What events could move ProMIS (PMN) Stock next | Price at $12.95, Up 2.78%Flat Correction - Newser
Major holders and board changes in ProMIS Neurosciences (PMN) 2026 proxy statement - Stock Titan
Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Neuramedy, Promis Neurosciences, Enterin Inc., Nippon Chemiphar - Mena FN
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can ProMIS Neurosciences Inc continue delivering strong returns2026 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Analysis Recap: Can ProMIS Neurosciences Inc continue delivering strong returnsQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
How does currency impact ProMIS (PMN) Stock | Price at $10.88, Down 0.73%Shared Buy Zones - Newser
ProMIS Neurosciences Shares Plunge Amid Critical Clinical Trial Phase - AD HOC NEWS
Janus Henderson (PMN) discloses 14.4% holding in PROMIS Neurosciences - Stock Titan
Is ProMIS (PMN) Stock Gaining Momentum | Price at $10.96, Down 12.39%Bullish Percent Index - The Legal Advocate
PMN Technical Analysis & Stock Price Forecast - Intellectia AI
Promis Neurosciences (NASDAQ:PMN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
PMN Faces Selling Pressure: Technical Levels to Watch - Xã Thanh Hà
Weekly Earnings: Will ProMIS Neurosciences Inc stock go up in YEARShare Buyback & Low Drawdown Investment Strategies - baoquankhu1.vn
Aug Volume: How does ProMIS Neurosciences Inc perform in inflationary periods2026 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
ProMIS Neurosciences Inc expected to post a loss of $1.91 a shareEarnings Preview - TradingView
[EFFECT] ProMIS Neurosciences Inc. SEC Filing - Stock Titan
Aug Mood: How cyclical is ProMIS Neurosciences Incs revenue stream2026 Institutional Moves & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):